Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

125.59 +1.89 (+1.53%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
43 44 Next >
The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the... 
Via Benzinga
Exposures Product Safety
Where Biogen Stands With Analysts
Biogen (NASDAQ:BIIB) has observed the following analyst ratings within the ... 
Via Benzinga
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
European Regulator Votes Down Biogen's Alzheimer's Drug
Following an oral explanation held at the November meeting of the EMA's human medicines committee, Biogen Inc (NASDAQ: BIIB) received "a negative trend vote... 
Via Benzinga
Biogen Stock Skids After Alzheimer's Drug Aduhelm Faces A Setback In Europe
The committee voted against recommending Aduhelm approval. 
Via Investor's Business Daily
Jim Cramer Likes This Stock Over Cassava Sciences And Biogen
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Cassava Sciences, Inc. (NASDAQ: 
Via Benzinga
Could Eli Lilly Leapfrog Biogen in This Market?
Biogen is benefiting from a first-mover advantage, but the race is far from over. 
Via The Motley Fool
Europe OKs Biogen's Vumerity For Multiple Sclerosis
The European Commission has approved Biogen Inc's (NASDAQ: BIIB) Vumerity (diroximel fumarate) to treat adults with relapsing-remitting multiple sclerosis (MS... 
Via Benzinga
Warren Buffet Takes A Stake In Royalty Pharma And Exits Merck — What You Need To Know
Warren Buffet's Berkshire Hathaway added more than 13 million shares. 
Via Investor's Business Daily
The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Kezar Life Sciences Reports Positive Interim Phase 2 Data For Lupus Nephritis... 
Via Benzinga
Google, Tesla Rival XPeng Lead 5 Stocks Near Buy Zones
A FANG giant and Tesla rival are among this diverse group. 
Via Investor's Business Daily
Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up
Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products. 
Via Talk Markets
President Biden Nominates Robert Califf As New FDA Commissioner: Report
Robert Califf was nominated today to lead the FDA for a second time. The White House reportedly ruled out Janet Woodcock after she faced opposition from some members of... 
Via Benzinga
Exposures Product Safety
Why Are Biogen Shares Gaining Today?
​​​​​​Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease. Related:... 
Via Benzinga
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded... 
Via Benzinga
Eisai Posts New Lecanemab Data From Mid-Stage Alzheimer's Trial
Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) announced results of sensitivity analyses evaluating the consistency of lecanemab efficacy results across... 
Via Benzinga
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Commences Late-Stage Study Of Heart Failure Treatment Merck &... 
Via Benzinga
Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters
With already a snail-paced rollout of Biogen Inc's (NASDAQ: BIIB) controversial Alzheimer's treatment Aduhelm, the Company could soon face price competition.... 
Via Benzinga
This Company Says Its New Topical Therapy Trials Bringing Hope to People Exposed to Biofilm Bacteria
Photo by Louis Reed on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner... 
Via Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
How Are Biotech ETFs Reacting To These Q3 Earnings Releases?
There's no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines. Let’s take a look at big biotech earnings releases to see... 
Via Talk Markets
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Todos Medical Says It Wants to Outfox COVID-19 & Cancer Along With Rivals Pfizer & Merck With New Theranostic Approach
Photo by Artem Podrez from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Exposures COVID-19
Healthcare Stocks Subject to Government Policy
The market this morning isn’t moving much, but today’s tepid start is coming on the heels of yesterday’s record closes on the Dow, the S&P 500, and the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Cassava Stock Could Jump More Than 200 Times
Cassava's Alzheimer's drug appears backed by strong data and plenty of public support. That's a winning combination for SAVA stock. 
Via InvestorPlace
Biogen Beat Earnings and Raised Guidance. Here's Why I Still Wouldn't Buy the Stock
Aduhelm remains a big question mark for the company. 
Via The Motley Fool
Will Chart Analysts Notice Bad Omen on Biogen's Chart
If history is any guide, there may be trouble ahead for shares of Biogen (NASDAQ:BIIB). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
Should Biogen Investors Be Preparing for the Worst?
With sagging sales and lackluster data in a recent trial, what does the future hold for shareholders? 
Via The Motley Fool
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
43 44 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.